Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 04, 2020 | |
Document And Entity Information | ||
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Entity Registrant Name | ARDELYX, INC. | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 89,056,759 | |
Entity Central Index Key | 0001437402 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
CONDENSED BALANCE SHEETS
CONDENSED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 105,895 | $ 181,133 |
Short-term investments | 117,312 | 66,379 |
Unbilled revenue | 750 | 750 |
Prepaid expenses and other current assets | 4,625 | 3,800 |
Total current assets | 228,582 | 252,062 |
Property and equipment, net | 2,968 | 3,436 |
Right-of-use assets | 3,468 | 3,970 |
Other assets | 304 | 314 |
Total assets | 235,322 | 259,782 |
Current liabilities: | ||
Accounts payable | 1,012 | 2,187 |
Accrued compensation and benefits | 1,951 | 4,453 |
Less: Current portion of operating lease liability | 2,715 | 2,608 |
Loan payable, current portion | 7,437 | 1,183 |
Deferred revenue | 3,366 | 4,541 |
Accrued expenses and other current liabilities | 6,936 | 7,248 |
Total current liabilities | 23,417 | 22,220 |
Operating lease liability, net of current portion | 1,355 | 2,076 |
Loan payable, net of current portion | 42,793 | 48,831 |
Total liabilities | 67,565 | 73,127 |
Commitments and contingencies (Note 10) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively. | ||
Common stock, $0.0001 par value; 300,000,000 shares authorized; 89,035,096 and 88,817,741 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively. | 9 | 9 |
Additional paid-in capital | 650,617 | 647,078 |
Accumulated deficit | (482,825) | (460,452) |
Accumulated other comprehensive (loss) income | (44) | 20 |
Total stockholders’ equity | 167,757 | 186,655 |
Total liabilities and stockholders’ equity | $ 235,322 | $ 259,782 |
CONDENSED BALANCE SHEETS (Paren
CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
CONDENSED BALANCE SHEETS (Parenthetical) | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 89,035,096 | 88,817,741 |
Common stock, shares outstanding | 89,035,096 | 88,817,741 |
CONDENSED STATEMENTS OF OPERATI
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenues: | ||
Total revenues | $ 1,213 | |
Operating expenses: | ||
Research and development | 15,844 | $ 20,381 |
General and administrative | 7,138 | 5,117 |
Total operating expenses | 22,982 | 25,498 |
Loss from operations | (21,769) | (25,498) |
Interest expense | (1,357) | (1,434) |
Other income, net | 753 | 790 |
Loss before provision for income taxes | (22,373) | (26,142) |
Provision for income taxes | 2 | |
Net loss | $ (22,373) | $ (26,144) |
Net loss per common share, basic and diluted | $ (0.25) | $ (0.42) |
Shares used in computing net loss per share - basic and diluted | 88,880,658 | 62,546,295 |
Comprehensive loss: | ||
Net loss | $ (22,373) | $ (26,144) |
Unrealized (losses) gains on available-for-sale securities | (64) | 50 |
Comprehensive loss | (22,437) | $ (26,094) |
Collaborative development | ||
Revenues: | ||
Total revenues | 1,175 | |
Other | ||
Revenues: | ||
Total revenues | $ 38 |
CONDENSED STATEMENTS OF CHANGES
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Income Income (Loss) | Total |
Balance, amount at Dec. 31, 2018 | $ 6 | $ 481,357 | $ (365,512) | $ (38) | $ 115,813 |
Balance, shares at Dec. 31, 2018 | 62,516,627 | ||||
Issuance of common stock under employee stock purchase plan, amount | 198 | 198 | |||
Issuance of common stock under employee stock purchase plan, shares | 83,046 | ||||
Issuance of common stock upon exercise of options, amount | 2 | 2 | |||
Issuance of common stock upon exercise of options, shares | 770 | ||||
Stock-based compensation | 1,922 | 1,922 | |||
Unrealized (losses) gains on available-for-sale securities | 50 | 50 | |||
Net loss | (26,144) | (26,144) | |||
Balance, amount at Mar. 31, 2019 | $ 6 | 483,479 | (391,656) | 12 | 91,841 |
Balance, shares at Mar. 31, 2019 | 62,600,443 | ||||
Balance, amount at Dec. 31, 2019 | $ 9 | 647,078 | (460,452) | 20 | 186,655 |
Balance, shares at Dec. 31, 2019 | 88,817,741 | ||||
Issuance of common stock under employee stock purchase plan, amount | 375 | 375 | |||
Issuance of common stock under employee stock purchase plan, shares | 75,804 | ||||
Issuance of common stock upon exercise of options, amount | 216 | 216 | |||
Issuance of common stock upon exercise of options, shares | 141,551 | ||||
Stock-based compensation | 2,948 | 2,948 | |||
Unrealized (losses) gains on available-for-sale securities | (64) | (64) | |||
Net loss | (22,373) | (22,373) | |||
Balance, amount at Mar. 31, 2020 | $ 9 | $ 650,617 | $ (482,825) | $ (44) | $ 167,757 |
Balance, shares at Mar. 31, 2020 | 89,035,096 |
CONDENSED STATEMENTS OF CASH FL
CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Operating activities | ||
Net loss | $ (22,373) | $ (26,144) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation expense | 492 | 675 |
Amortization of deferred financing costs | 112 | 120 |
Amortization of deferred compensation for services | 89 | 76 |
Amortization of premium on investment securities | (138) | (301) |
Non-cash lease expense | 502 | 439 |
Stock-based compensation | 2,948 | 1,922 |
Change in derivative liabilities | 82 | 37 |
Non-cash interest associated with debt discount accretion | 127 | 113 |
Changes in operating assets and liabilities: | ||
Unbilled revenue | 5,000 | |
Prepaid expenses and other assets | (928) | 411 |
Accounts payable | (1,174) | 777 |
Accrued compensation and benefits | (2,502) | (1,089) |
Lease liabilities | (614) | |
Accrued and other liabilities | (394) | 1,051 |
Deferred revenue | (1,175) | |
Net cash used in operating activities | (24,946) | (16,913) |
Investing activities | ||
Proceeds from maturities of investments | 4,000 | 55,020 |
Purchases of investments | (54,858) | (24,874) |
Purchases of property and equipment | (25) | (165) |
Net cash (used in) provided by investing activities | (50,883) | 29,981 |
Financing activities | ||
Proceeds from issuance of common stock under stock plans | 375 | 198 |
Issuance of common stock upon exercise of options | 216 | 2 |
Net cash provided by financing activities | 591 | 200 |
Net (decrease) increase in cash and cash equivalents | (75,238) | 13,268 |
Cash and cash equivalents at beginning of period | 181,133 | 78,768 |
Cash and cash equivalents at end of period | $ 105,895 | 92,036 |
Supplementary disclosure of cash flow information: | ||
Income taxes paid | 2 | |
Supplementary disclosure of non-cash activities: | ||
Right-of-use assets obtained in exchange for lease obligations | $ 5,810 |
Organization and Basis of Prese
Organization and Basis of Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Organization and Basis of Presentation | |
Organization and Basis of Presentation | NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION Ardelyx, Inc. (the “Company,” “we,” “us” or “our”) is a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases. The Company operates in one business segment, which is the research and development of biopharmaceutical products . Basis of Presentation These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as the Company’s most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2020 and results of operations, changes in stockholders’ equity, and cash flows for the interim periods ended March 31, 2020 and 2019. The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K the year ended December 31, 2019. The results for the three months ended March 31, 2020, are not necessarily indicative of results to be expected for the entire year ending December 31, 2020, or any other interim period or future year. Prior Period Errors In connection with our review of our financial statements as of and for the six months ended June 30, 2019, we corrected errors related to the accounting for clinical trial accruals that had resulted in an overstatement of research and development expenses during the three months ended March 31, 2019 and during the year ended December 31, 2018. Specifically, management concluded that the Company’s research and development expenses recorded during the three months ended March 31, 2019 and during year ended December 31, 2018 had been overstated by $0.5 million and $3.6 million, respectively, and that the Company’s accrued expenses and other current liabilities for these periods had been overstated by the same amounts . Management analyzed the potential impact of these errors in accordance with the SEC’s Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements , and concluded that while the errors were significant to the Company’s financial statements as of and for the six months ended June 30, 2019, a correction of the errors would not have been material to each quarter or the full year results for 2019 and 2018 nor affect the trend of financial results . Accordingly, during the second quarter of 2019, the Company reduced accrued and other liabilities by $4.1 million and recorded a cumulative adjustment of $4.1 million in the condensed statement of operations to reduce research and development expenses. Liquidity As of March 31, 2020, the Company had cash, cash equivalents and short-term investments of approximately $223.2 million. The Company believes its current available cash, cash equivalents and short-term investments will be sufficient to fund the Company’s planned expenditures and meet its obligations for at least 12 months following May 7, 2020, which is the date that these condensed financial statements are being issued. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. Summary of Significant Accounting Policies There have been no changes to the significant accounting policies disclosed in the Company’s most recent Annual Report on Form 10‑K. Recently Adopted Accounting Pronouncements In November 2018, the Financial Accounting Standards Board (“ FASB”) issued Accounting Standards Update (“ASU”) 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under the FASB’s Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers (“ASC 606”) when the collaborative arrangement participant is a customer. The Company adopted ASU 2018-18 on January 1, 2020, and t he adoption of this standard did not have a material impact on the Company’s financial statements . In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which considers cost and benefits and removes, modifies and adds disclosure requirements in Topic 820. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty is to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments were to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 on January 1, 2020, and the adoption of this standard did not have a material impact on the Company’s financial statements . Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which removes certain exceptions for intra period allocations, recognizing deferred taxes for investments and calculating income taxes in interim periods. This ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. The guidance is effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Management is currently assessing the impact of this standard on the Company’s financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. Management is currently assessing the impact of this standard on the Company’s financial statements. |
Cash, Cash Equivalents and Shor
Cash, Cash Equivalents and Short-Term Investments | 3 Months Ended |
Mar. 31, 2020 | |
Cash, Cash Equivalents and Short-Term Investments | |
Cash, Cash Equivalents and Short-Term Investments | NOTE 2. CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Securities classified as cash, cash equivalents and short-term investments as of March 31, 2020 and December 31, 2019, are summarized below. March 31, 2020 Gross Unrealized Amortized Cost Gains Losses Fair Value Cash and cash equivalents: Money market funds $ 100,755 $ — $ — $ 100,755 Commercial paper 3,999 — — 3,999 Cash 1,141 — — 1,141 Total cash and cash equivalents 105,895 — — 105,895 Short-term investments Commercial paper $ 53,605 $ 106 $ — $ 53,711 Corporate bonds 49,245 10 (133) 49,122 Asset-backed securities 10,510 — (52) 10,458 U.S. treasury notes 3,996 25 — 4,021 Total short-term investments 117,356 141 (185) 117,312 Total cash equivalents and short-term investments $ 223,251 $ 141 $ (185) $ 223,207 December 31, 2019 Gross Unrealized Amortized Cost Gains Losses Fair Value Cash and cash equivalents: Money market funds $ 147,208 $ — $ — $ 147,208 Commercial paper 19,357 3 — 19,360 Corporate bonds 11,441 — — 11,441 Cash 3,124 — — 3,124 Total cash and cash equivalents 181,130 3 — 181,133 Short-term investments Commercial paper $ 36,667 $ 14 $ — $ 36,681 Corporate bonds 21,690 6 (3) 21,693 Asset-backed securities 8,005 — — 8,005 Total short-term investments 66,362 20 (3) 66,379 Total cash equivalents and short-term investments $ 247,492 $ 23 $ (3) $ 247,512 All available-for-sale securities held as of March 31, 2020 had contractual maturities of less than one year. The Company’s available-for-sale securities are subject to a periodic impairment review. The Company considers a debt security to be impaired when the fair value of that security is less than its carrying cost, in which case the Company would further evaluate the investment to determine whether the security is other-than-temporarily impaired. When the Company evaluates an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below cost basis, the financial condition or creditworthiness of the issuer and any changes thereto, intent to sell, and whether it is more likely than not the Company will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, the Company writes the investment down through the statement of operations to its fair value and establishes that value as the new cost basis for the investment. Management has determined that none of the Company’s available-for-sale securities were other-than-temporarily impaired in any of the periods presented, and as of March 31, 2020, no investment was in a continuous unrealized loss position for more than one year. As such, the Company believes that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers, which could result in a default by one or more issuers or result in downgrades below our minimum credit rating requirements. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Measurements | |
Fair Value Measurements | NOTE 3. FAIR VALUE MEASUREMENTS The Company’s financial instruments consist of cash and cash equivalents, short-term investments, prepaid expenses, other current assets, accounts payable, accrued expenses, and the Term Loan, as defined and discussed in Note 5. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment. The carrying amounts of financial instruments such as cash and cash equivalents, prepaid expenses, other current assets, accounts payable and accrued expenses approximate the related fair values due to the short maturities of these instruments. Based on prevailing borrowing rates available to the Company for loans with similar terms, the Company believes the fair value of the Term Loan, considering level 2 inputs, approximates this instrument’s carrying value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 – Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by the Company at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets. Level 2 – Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 2 inputs are corporate bonds, commercial paper, certificates of deposit and over-the-counter derivatives. Level 3 – Valuations based on unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions. The following table sets forth the fair value of the Company’s financial assets and liabilities that are measured or disclosed on a recurring basis: March 31, 2020 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 100,755 $ 100,755 $ — $ — Commercial paper 57,710 — 57,710 — Corporate bonds 49,122 — 49,122 — Asset-backed securities 10,458 — 10,458 — U.S. treasury notes 4,021 4,021 — — Total $ 222,066 $ 104,776 $ 117,290 $ — Liabilities: Derivative liability for Exit Fee $ 1,051 $ — $ — $ 1,051 Total $ 1,051 $ — $ — $ 1,051 December 31, 2019 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 147,208 $ 147,208 $ — $ — Commercial paper 56,041 — 56,041 — Corporate bonds 33,134 — 33,134 — Asset-backed securities 8,005 — 8,005 — Total $ 244,388 $ 147,208 $ 97,180 $ — Liabilities: Derivative liability for Exit Fee $ 969 $ — $ — $ 969 Total $ 969 $ — $ — $ 969 Where quoted prices are available in an active market, securities are classified as Level 1. The Company classifies money market funds, U.S. treasury securities and U.S. treasury notes as Level 1. When quoted market prices are not available for the specific security, the Company estimates fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. The Company classifies corporate bonds, commercial paper, asset-backed securities and foreign currency derivative contracts as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities such as the Exit Fee, as defined and discussed in Note 4, are classified as Level 3. There were no transfers between Level 1 and Level 2 during the periods presented. |
Derivative Liability
Derivative Liability | 3 Months Ended |
Mar. 31, 2020 | |
Derivative Liability | |
Derivative Liability | NOTE 4. DERIVATIVE LIABILITY In May 2018, in connection with entering into the Loan Agreement, as defined and discussed in Note 5, the Company entered into an agreement pursuant to which the Company agreed to pay $1.5 million in cash (the “Exit Fee”) upon any change of control transaction in respect of the Company or if the Company obtains both (i) U.S. Food and Drug Administration (“ FDA”) approval of tenapanor for the treatment of hyperphosphatemia in chronic kidney disease (“CKD”) patients on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (“IBS-C”), which was obtained on September 12, 2019 when the FDA approved IBSRELA ® (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the “Exit Fee Agreement”) . Notwithstanding the prepayment or termination of the Term Loan, as defined and discussed in Note 5, the Company’s obligation to pay the Exit Fee will expire on May 16, 2028. The Company concluded that the Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. The fair value of the derivative liability was determined using a discounted cash flow analysis, and the key assumptions included in the calculation of the estimated fair value of the derivative liability include: (i) the Company’s estimates of both the probability and timing of payment of the Exit Fee to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals and (ii) a variable discount rate. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability, and it is estimated that a 10% increase or decrease in the probability of occurrence would result in a fair value fluctuation of approximately $0.1 million. Changes in fair value, which are presented as other income, net, in the Company's condensed statements of operations, were as follows: Three Months Ended March 31, 2020 2019 Fair value of Exit Fee derivative liability at January 1 $ 969 $ 533 Change in estimated fair value of derivative liability 82 37 Fair value of Exit Fee derivative liability at March 31 $ 1,051 $ 570 |
Borrowing
Borrowing | 3 Months Ended |
Mar. 31, 2020 | |
Borrowing | |
Borrowing | NOTE 5. BORROWING Solar Capital and Western Alliance Bank Loan Agreement On May 16, 2018, Borrowings under the Term Loan bear interest at a floating per annum rate equal to 7.45% plus the one-month LIBOR. The Company is permitted to make interest-only payments on the Term Loan through June 1, 2020, unless prior to that date the Company achieves its primary endpoint in the Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis (the “Phase 3 Endpoint”), in which case the Company is permitted to make interest-only payments on the Term Loan until December 1, 2020. On December 3, 2019, the Company reported positive topline results for PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of hyperphosphatemia in patients with CKD on dialysis. The Lenders are in agreement that these positive data from the Phase 3 PHREEDOM study meet the definition of the Phase 3 Endpoint . Accordingly, beginning on December 1, 2020 and through the maturity date, in addition to monthly interest payments, the Company will be required to make monthly principal payments in equal monthly installments of approximately $2.1 million. The Company paid a closing fee of 1% of the Term Loan, or $0.5 million, upon the closing of the Term Loan, and the Company is obligated to pay a final fee equal to 3.95% of the Term Loan upon the earliest to occur of the maturity date, the acceleration of the Term Loan, the prepayment or repayment of the Term Loan or the termination of the Loan Agreement. The Company may voluntarily prepay the outstanding Term Loan, subject to a prepayment premium of (i) 3% of the principal amount of the Term Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The Term Loan is secured by substantially all the Company’s assets, except for the Company’s intellectual property and certain other customary exclusions. Additionally, in connection with the Term Loan, the Company entered into the Exit Fee Agreement , as discussed in Note 4 . The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants. As of March 31, 2020, the Company was in compliance with all of the covenants set forth in the Loan Agreement. The Loan Agreement also contains customary events of default that entitle the Lender to cause the Company’s indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the Term Loan, including the Company’s cash. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4.0% per annum will apply to all amounts owed under the Loan Agreement. As of March 31, 2020, to the Company’s knowledge, there were no facts or circumstances in existence that would give rise to an event of default. As of March 31, 2020, the Company’s future payment obligations related to the Term Loan, excluding interest payments and the Exit Fee, are as follows : Remainder of 2020 $ 2,083 2021 25,000 2022 24,892 Total principal and final fee payments 51,975 Less: Unamortized discount and debt issuance costs (652) Less: Unaccreted value of final fee (1,093) Loan payable 50,230 Less: Loan payable, current portion 7,437 Loan payable, net of current portion $ 42,793 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2020 | |
Leases | |
Leases | NOTE 6. LEASES All of the Company’s leases, which primarily include the right to use office and laboratory space, are operating leases, and certain of the leases have both lease and non-lease components. The Company has elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. The following table provides additional details related to our facility leases, as presented in the Company’s condensed balance sheet as of March 31, 2020: Facilities Right of use assets $ 3,468 Current portion of lease liabilities 2,715 Operating lease liability, net of current portion 1,355 Total $ 4,070 Weighted-average remaining life (years) Weighted-average discount rate % Other information related to the Company’s facilities lease is as follows: Three Months Ended March 31, 2020 2019 Operating lease expense $ $ 648 Cash paid for operating lease $ $ 614 The following table summarizes the Company’s undiscounted cash payment obligations for its operating lease liabilities as of March 31, 2020: Remainder of 2020 $ 2,306 2021 2,183 Total undiscounted operating lease payments 4,489 Imputed interest expenses (419) Total operating lease liabilities 4,070 Less: Current portion of operating lease liability 2,715 Operating lease liability, net of current portion $ 1,355 |
Equity Incentive Plans
Equity Incentive Plans | 3 Months Ended |
Mar. 31, 2020 | |
Equity Incentive Plans | |
Equity Incentive Plans | NOTE 7. EQUITY INCENTIVE PLANS Stock Option Plan During the three months ended March 31, 2020, options were granted to employees to purchase 1,919,789 shares. The weighted-average grant-date estimated fair value of options granted during the three months ended March 31, 2020 was $5.27. The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following weighted-average assumptions: Three Months Ended March 31, 2020 Expected term (years) 6.00 Expected volatility 83.62 % Risk-free interest rate 1.68 % Dividend yield — % During the three months ended March 31, 2020 and 2019, options were exercised to purchase 141,551 and 770 shares, respectively, of the Company's common stock, resulting in approximately $0.2 million and insignificant net proceeds to the Company in the three months ended March 31, 2020 and 2019, respectively. Restricted Stock Units (“RSUs”) In July 2018, the Company granted 903,374 performance-based restricted stock units (“PRSUs”) to its employees that vest upon the achievement of certain performance conditions, subject to the employees’ continued service relationship with the Company through the achievement date. As of March 31, 2020, 849,328 of these PRSUs were outstanding and none of these PRSUs were vested . Based on the evaluation of the performance conditions, the Company recorded stock-based compensation expense of $0.9 million and zero for the three months ended March 31, 2020 and 2019, respectively. The related compensation cost is recognized as an expense ratably over the estimated vesting period. The expense recognized for these awards is based on the grant date fair value of the Company’s common stock multiplied by the number of units granted. No RSUs or PRSUs were granted during the three months ended March 31, 2020 or 2019. Similarly, no common shares were issued upon vesting of time-based RSUs during these periods. Employee Stock Purchase Plan In February 2020, the Company sold 75,804 shares of its common stock under the Company’s employee stock purchase program (“ESPP”). The shares were purchased by employees at a purchase price of $4.95 per share with proceeds to the Company of approximately $0.4 million. Stock-Based Compensation Stock-based compensation expense recognized for stock options, RSUs, PRSUs and the Company’s ESPP are recorded as operating expenses in the Company’s condensed statements of operations and comprehensive loss, as follows: Three Months Ended March 31, 2020 2019 Research and development $ 1,058 $ 760 General and administrative 1,890 1,162 Total $ 2,948 $ 1,922 As of March 31, 2020, the Company’s total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following: Unrecognized Compensation Expense Average Remaining Vesting Period (Years) Stock options $ 13,401 3.0 PRSUs $ 602 0.4 ESPP $ 194 0.4 |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2020 | |
Net Loss Per Share | |
Net Loss Per Share | NOTE 8. NET LOSS PER SHARE Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As the Company had net losses for the three months ended March 31, 2020 and 2019, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of net loss per common share: Three Months Ended 2020 2019 Numerator: Net loss $ (22,373) $ (26,144) Denominator: Weighted average common shares outstanding - basic and diluted 88,880,658 62,546,295 Net loss per share - basic and diluted $ (0.25) $ (0.42) For the three months ended March 31, 2020 and 2019, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 11.9 million and 9.9 million, respectively. |
Collaboration and Licensing Agr
Collaboration and Licensing Agreements | 3 Months Ended |
Mar. 31, 2020 | |
Collaboration and Licensing Agreements | |
Collaboration and Licensing Agreements | NOTE 9. COLLABORATION AND LICENSING AGREEMENTS Kyowa Kirin Co., Ltd. (“KKC”) 2019 KKC Agreement In November 2019, the Company entered into a research collaboration and option agreement with KKC (the “2019 KKC Agreement”) for research associated with identifying two pre-clinical compounds that are ready for designation as development compounds, with one compound inhibiting the first undisclosed target (“Program 1”), and a second inhibiting the second undisclosed target (“Program 2”). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more development candidates (“DCs”), KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories. Under the terms of the 2019 KKC Agreement, KKC agreed to pay the Company a non-refundable, non-creditable upfront fee of $10.0 million, payable as follows: the first installment of $5.0 million within 30 days of November 11, 2019 (the “Effective Date”), and the second installment of $5.0 million on the first anniversary of the Effective Date, unless the 2019 KKC Agreement is earlier terminated by KKC due to material breach by the Company. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) two years following the Effective Date, or (ii) the nomination of a program DC for both programs, (iii) or the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. The Company assessed the 2019 KKC Agreement in accordance with ASC 606 and concluded that the contract’s counterparty, KKC, is a customer. Management also considered the modification guidance prescribed in ASC 606 and concluded that the 2019 KKC Agreement should be accounted for as a separate contract from the 2017 KKC Agreement, as defined and discussed below. The Company identified various promises in the 2019 KKC Agreement, including: the grant of an initial research license; the Program 1 research; the Program 2 research; the right to obtain certain development and commercialization rights to a Program 1 DC in certain territories; the right to obtain development and commercialization rights to a Program 2 DC in certain territories; and participation in a joint steering committee (“JSC”). The Company determined that KKC could not benefit from either of the research programs without the research license and participation in the JSC. As such, the combined license, research programs and participation in the JSC were deemed to be the highest level of goods and services that can be deemed distinct for each of the Program 1 research and Program 2 research. The Company concluded that the options to obtain additional development and commercialization rights that are exercisable by KKC under certain circumstances are not performance obligations of the contract at inception because the option fees reflect the standalone selling price of the options, and therefore, the options are not considered to be material rights. At the outset of the 2019 KKC Agreement, the Company determined that the initial transaction price amounted to $10.0 million and that revenue associated with the combined performance obligations will be recognized as services are provided using an input method. Since transfer of control occurs over time, in management’s judgment this input method is the best measure of progress towards satisfying the performance obligations and reflects a faithful depiction of the transfer of goods and services . Revenue will be recognized over the Program 1 and Program 2 research periods, which are currently expected to extend through the end of 2021. Management will re-evaluate the estimates related to the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and adjust the timing of revenue recognition as necessary. During the three months ended March 31, 2020, the Company recognized $1.2 million as revenue under the 2019 KKC Agreement in the statement of operations and comprehensive loss. The aggregate amount of the transaction price allocated to the Company’s partially unsatisfied performance obligations as of March 31, 2020 was $8.4 million, of which $3.4 million is presented in the accompanying condensed balance sheet as deferred revenue. As of March 31, 2020, the Company expects to recognize the remaining transaction price allocated to the Company’s partially unsatisfied performance obligations over the remaining research terms, which, as noted above, are currently expected to extend through the end of 2021. There were no changes in estimates associated with the 2019 KKC Agreement during the three months ended March 31, 2020. 2017 KKC Agreement In November 2017, the Company entered into an exclusive license agreement with KKC (the “2017 KKC Agreement”), for the development, commercialization and distribution of tenapanor in Japan for cardiorenal indications. The Company granted KKC an exclusive license to develop and commercialize certain sodium hydrogen exchanger 3 (“ NHE3”) inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. The Company retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for the treatment of cardiorenal diseases and conditions, excluding cancer in Japan. Under the 2017 KKC Agreement, the Company is responsible for supplying the tenapanor drug product for KKC’s use in development and during commercialization until KKC has assumed such responsibility. Additionally, the Company is responsible for supplying the tenapanor drug substance for KKC’s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions. The Company assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, the Company received $30.0 million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on the Company’s assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. Additionally, the Company recorded unbilled revenue of $5.0 million and an increase in uncharged license fees of $1.0 million related to the first milestone under the 2017 KKC Agreement that KKC; this first milestone was achieved in February 2019. In addition to the $30.0 million upfront license fee, the Company may be entitled to receive up to $55.0 million in total development milestones, of which $5.0 million has been received to date, and approximately $78.3 million in commercialization milestones, as well as reimbursement of costs plus a reasonable overhead for the supply of product and high-teen royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March 31, 2020. During the three months ended March 31, 2020 and 2019, the Company recognized $38,000 and zero, respectively, as other revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. Xuanzhu (HK) Biopharmaceutical Limited (“XuanZhu”) In November 2019, the Company entered into a license agreement with XuanZhu (the “XuanZhu Agreement”), pursuant to which the Company granted XuanZhu a license to certain specific patent and patent applications. The Company assessed the XuanZhu Agreement in accordance with ASC 606 and concluded that the contract counterparty, XuanZhu, is a customer. Under the terms of the XuanZhu Agreement, the Company recognized $1.5 million in license fees, which constituted the initial transaction price, when the agreement was executed, of which $750,000 was received upfront in November 2019, and achievement for the second $750,000 payment, related to the issuance and grant of a specific patent, was determined to be not materially at risk and probable of achievement. Based on management’s assessment, the Company determined that it has one combined performance obligation, which is the license and the specific patent grant. No revenue related to the XuanZhu Agreement was recorded during the three months ended March 31, 2020. Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (“Fosun Pharma”) In December 2017, the Company entered into an exclusive license agreement with Fosun Pharma (the “Fosun Agreement”), for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. The Company assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, the Company received $12.0 million in upfront license fees which was recognized as revenue when the agreement was executed. Based on management’s assessment, the Company determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct . The Company may be entitled to additional development and commercialization milestones of up to $110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to 20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March 31, 2020. The Company has recorded no revenue during the three months ended March 31, 2020 or 2019 related to the Fosun Agreement. Knight Therapeutics, Inc. (“Knight“) In March 2018, the Company entered into an exclusive license agreement with Knight (the “Knight Agreement”), for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management’s assessment, the Company determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, the Company is eligible to receive up to $17.6 million, including an upfront payment, development and sales milestones, reimbursement of supply costs on a schedule specifying cost per tablet, with a reasonable mark up for overhead, as well as tiered royalty rates on net sales ranging from the mid-single digits to the low twenties. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March 31, 2020. During the three months ended March 31, 2020 and 2019, no revenue was recorded related to the Knight Agreement. The following table presents changes in the Company’s deferred revenue balance, which is attributable entirely to the 2019 KKC Agreement discussed above, during the reporting period: Deferred revenue Balance at December 31, 2019 $ 4,541 Increases due to cash received, excluding amounts recognized as revenue during the period — Decreases due to revenue recognized in the period for which cash has been received (588) Decreases due to revenue recognized in the period for which cash has not been received (587) Balance at March 31, 2020 $ 3,366 |
Contingencies
Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Contingencies. | |
Contingencies | NOTE 10. CONTINGENCIES From time to time the Company may be involved in claims arising in connection with its business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against the Company will not be material to the Company’s financial condition or cash flows, and no contingent liabilities were accrued as of March 31, 2020 or 2019. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2020 | |
Income Taxes | |
Income Taxes | NOTE 11. INCOME TAXES On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes, among other features, provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. While the Company continues to evaluate the impact of the CARES Act, it does not expect the provisions of the legislation to have a significant impact on the effective tax rate or on the income tax provision or deferred income tax positions of the Company. |
Organization and Basis of Pre_2
Organization and Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Summary of Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as the Company’s most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2020 and results of operations, changes in stockholders’ equity, and cash flows for the interim periods ended March 31, 2020 and 2019. The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K the year ended December 31, 2019. The results for the three months ended March 31, 2020, are not necessarily indicative of results to be expected for the entire year ending December 31, 2020, or any other interim period or future year. |
Prior Period Errors | Prior Period Errors In connection with our review of our financial statements as of and for the six months ended June 30, 2019, we corrected errors related to the accounting for clinical trial accruals that had resulted in an overstatement of research and development expenses during the three months ended March 31, 2019 and during the year ended December 31, 2018. Specifically, management concluded that the Company’s research and development expenses recorded during the three months ended March 31, 2019 and during year ended December 31, 2018 had been overstated by $0.5 million and $3.6 million, respectively, and that the Company’s accrued expenses and other current liabilities for these periods had been overstated by the same amounts . Management analyzed the potential impact of these errors in accordance with the SEC’s Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements , and concluded that while the errors were significant to the Company’s financial statements as of and for the six months ended June 30, 2019, a correction of the errors would not have been material to each quarter or the full year results for 2019 and 2018 nor affect the trend of financial results . Accordingly, during the second quarter of 2019, the Company reduced accrued and other liabilities by $4.1 million and recorded a cumulative adjustment of $4.1 million in the condensed statement of operations to reduce research and development expenses. |
Liquidity | Liquidity As of March 31, 2020, the Company had cash, cash equivalents and short-term investments of approximately $223.2 million. The Company believes its current available cash, cash equivalents and short-term investments will be sufficient to fund the Company’s planned expenditures and meet its obligations for at least 12 months following May 7, 2020, which is the date that these condensed financial statements are being issued. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. |
Recent Accounting Pronouncements | Recently Adopted Accounting Pronouncements In November 2018, the Financial Accounting Standards Board (“ FASB”) issued Accounting Standards Update (“ASU”) 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under the FASB’s Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers (“ASC 606”) when the collaborative arrangement participant is a customer. The Company adopted ASU 2018-18 on January 1, 2020, and t he adoption of this standard did not have a material impact on the Company’s financial statements . In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which considers cost and benefits and removes, modifies and adds disclosure requirements in Topic 820. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty is to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments were to be applied retrospectively to all periods presented. The Company adopted ASU 2018-13 on January 1, 2020, and the adoption of this standard did not have a material impact on the Company’s financial statements . Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which removes certain exceptions for intra period allocations, recognizing deferred taxes for investments and calculating income taxes in interim periods. This ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. The guidance is effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Management is currently assessing the impact of this standard on the Company’s financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. Management is currently assessing the impact of this standard on the Company’s financial statements. |
Fair Value Measurements | The Company’s financial instruments consist of cash and cash equivalents, short-term investments, prepaid expenses, other current assets, accounts payable, accrued expenses, and the Term Loan, as defined and discussed in Note 5. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment. The carrying amounts of financial instruments such as cash and cash equivalents, prepaid expenses, other current assets, accounts payable and accrued expenses approximate the related fair values due to the short maturities of these instruments. Based on prevailing borrowing rates available to the Company for loans with similar terms, the Company believes the fair value of the Term Loan, considering level 2 inputs, approximates this instrument’s carrying value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 – Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by the Company at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets. Level 2 – Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 2 inputs are corporate bonds, commercial paper, certificates of deposit and over-the-counter derivatives. Level 3 – Valuations based on unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions. |
Cash, Cash Equivalents and Sh_2
Cash, Cash Equivalents and Short-Term Investments (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Cash, Cash Equivalents and Short-Term Investments | |
Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments | March 31, 2020 Gross Unrealized Amortized Cost Gains Losses Fair Value Cash and cash equivalents: Money market funds $ 100,755 $ — $ — $ 100,755 Commercial paper 3,999 — — 3,999 Cash 1,141 — — 1,141 Total cash and cash equivalents 105,895 — — 105,895 Short-term investments Commercial paper $ 53,605 $ 106 $ — $ 53,711 Corporate bonds 49,245 10 (133) 49,122 Asset-backed securities 10,510 — (52) 10,458 U.S. treasury notes 3,996 25 — 4,021 Total short-term investments 117,356 141 (185) 117,312 Total cash equivalents and short-term investments $ 223,251 $ 141 $ (185) $ 223,207 December 31, 2019 Gross Unrealized Amortized Cost Gains Losses Fair Value Cash and cash equivalents: Money market funds $ 147,208 $ — $ — $ 147,208 Commercial paper 19,357 3 — 19,360 Corporate bonds 11,441 — — 11,441 Cash 3,124 — — 3,124 Total cash and cash equivalents 181,130 3 — 181,133 Short-term investments Commercial paper $ 36,667 $ 14 $ — $ 36,681 Corporate bonds 21,690 6 (3) 21,693 Asset-backed securities 8,005 — — 8,005 Total short-term investments 66,362 20 (3) 66,379 Total cash equivalents and short-term investments $ 247,492 $ 23 $ (3) $ 247,512 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Measurements | |
Summary of Fair Value Measurements of Company's Financial Assets and Liabilities | March 31, 2020 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 100,755 $ 100,755 $ — $ — Commercial paper 57,710 — 57,710 — Corporate bonds 49,122 — 49,122 — Asset-backed securities 10,458 — 10,458 — U.S. treasury notes 4,021 4,021 — — Total $ 222,066 $ 104,776 $ 117,290 $ — Liabilities: Derivative liability for Exit Fee $ 1,051 $ — $ — $ 1,051 Total $ 1,051 $ — $ — $ 1,051 December 31, 2019 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 147,208 $ 147,208 $ — $ — Commercial paper 56,041 — 56,041 — Corporate bonds 33,134 — 33,134 — Asset-backed securities 8,005 — 8,005 — Total $ 244,388 $ 147,208 $ 97,180 $ — Liabilities: Derivative liability for Exit Fee $ 969 $ — $ — $ 969 Total $ 969 $ — $ — $ 969 |
Derivative Liability (Tables)
Derivative Liability (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Derivative Liability | |
Schedule of Changes in Fair Value | Three Months Ended March 31, 2020 2019 Fair value of Exit Fee derivative liability at January 1 $ 969 $ 533 Change in estimated fair value of derivative liability 82 37 Fair value of Exit Fee derivative liability at March 31 $ 1,051 $ 570 |
Borrowing (Tables)
Borrowing (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Borrowing | |
Schedule of Future Debt Payment Obligations | Remainder of 2020 $ 2,083 2021 25,000 2022 24,892 Total principal and final fee payments 51,975 Less: Unamortized discount and debt issuance costs (652) Less: Unaccreted value of final fee (1,093) Loan payable 50,230 Less: Loan payable, current portion 7,437 Loan payable, net of current portion $ 42,793 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Leases | |
Summary of Additional Details of the Leases | Facilities Right of use assets $ 3,468 Current portion of lease liabilities 2,715 Operating lease liability, net of current portion 1,355 Total $ 4,070 Weighted-average remaining life (years) Weighted-average discount rate % |
Summary of Lease Costs | Three Months Ended March 31, 2020 2019 Operating lease expense $ $ 648 Cash paid for operating lease $ $ 614 |
Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities | Remainder of 2020 $ 2,306 2021 2,183 Total undiscounted operating lease payments 4,489 Imputed interest expenses (419) Total operating lease liabilities 4,070 Less: Current portion of operating lease liability 2,715 Operating lease liability, net of current portion $ 1,355 |
Equity Incentive Plans (Tables)
Equity Incentive Plans (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Equity Incentive Plans | |
Summary of Weighted-Average Assumptions to Estimate Fair Value of Employee Stock Options | Three Months Ended March 31, 2020 Expected term (years) 6.00 Expected volatility 83.62 % Risk-free interest rate 1.68 % Dividend yield — % |
Summary of Stock-Based Compensation Expense Recognized | Three Months Ended March 31, 2020 2019 Research and development $ 1,058 $ 760 General and administrative 1,890 1,162 Total $ 2,948 $ 1,922 |
Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures | Unrecognized Compensation Expense Average Remaining Vesting Period (Years) Stock options $ 13,401 3.0 PRSUs $ 602 0.4 ESPP $ 194 0.4 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Net Loss Per Share | |
Computation of Basic and Diluted Loss Per Share Attributable to Common Stockholders | Three Months Ended 2020 2019 Numerator: Net loss $ (22,373) $ (26,144) Denominator: Weighted average common shares outstanding - basic and diluted 88,880,658 62,546,295 Net loss per share - basic and diluted $ (0.25) $ (0.42) |
Collaboration and Licensing A_2
Collaboration and Licensing Agreements (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Collaboration and Licensing Agreements | |
Schedule of Changes in Deferred Revenue | Deferred revenue Balance at December 31, 2019 $ 4,541 Increases due to cash received, excluding amounts recognized as revenue during the period — Decreases due to revenue recognized in the period for which cash has been received (588) Decreases due to revenue recognized in the period for which cash has not been received (587) Balance at March 31, 2020 $ 3,366 |
Organization and Basis of Pre_3
Organization and Basis of Presentation - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2020segment | |
Organization and Basis of Presentation | |
Number of operating segments | 1 |
Organization and Basis of Pre_4
Organization and Basis of Presentation - Prior Period Errors (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2019 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Research and Development Expense | $ 15,844 | $ 20,381 | ||
Accrued Liabilities and Other Liabilities | $ 6,936 | $ 7,248 | ||
Overstatement due to clinical trial accrual errors | Effect of Change | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Research and Development Expense | 500 | $ 3,600 | ||
Accrued Liabilities and Other Liabilities | $ 500 | $ 3,600 |
Organization and Basis of Pre_5
Organization and Basis of Presentation - Cumulative adjustments (Details) $ in Millions | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Reduction in accrued and other liabilities | |
Quantifying Misstatement in Current Year Financial Statements [Line Items] | |
Correction of cumulative errors | $ 4.1 |
Reduction in research and development expenses | |
Quantifying Misstatement in Current Year Financial Statements [Line Items] | |
Correction of cumulative errors | $ 4.1 |
Organization and Basis of Pre_6
Organization and Basis of Presentation - Liquidity (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Organization and Basis of Presentation | ||
Cash and cash equivalents and short-term investments | $ 223,251 | $ 247,492 |
Cash, Cash Equivalents and Sh_3
Cash, Cash Equivalents and Short-Term Investments - Schedule of Securities Classified as Cash, Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Cash and cash equivalents, Amortized Cost | $ 105,895 | $ 181,133 | $ 92,036 | $ 78,768 |
Cash and cash equivalents, Amortized Cost | 181,130 | |||
Cash and cash equivalents, Gross Unrealized Gains | 3 | |||
Cash and cash equivalents, Fair Value | 105,895 | 181,133 | ||
Short-term investments, Amortized Cost | 117,356 | 66,362 | ||
Short-term investments, Gross Unrealized Gains | 141 | 20 | ||
Short-term investments, Gross Unrealized Losses | (185) | (3) | ||
Short-term investments, Fair Value | 117,312 | 66,379 | ||
Cash equivalents and short-term investments, Amortized Cost | 223,251 | 247,492 | ||
Cash equivalents and short-term investments, Gross Unrealized Gains | 141 | 23 | ||
Cash equivalents and short-term investments, Gross Unrealized Losses | (185) | (3) | ||
Cash equivalents and short-term investments, Fair Value | 223,207 | 247,512 | ||
Money Market Funds [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Cash and cash equivalents, Amortized Cost | 100,755 | 147,208 | ||
Cash and cash equivalents, Fair Value | 100,755 | 147,208 | ||
Commercial Paper (Cash Equivalents) [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Cash and cash equivalents, Amortized Cost | 3,999 | 19,357 | ||
Cash and cash equivalents, Gross Unrealized Gains | 3 | |||
Cash and cash equivalents, Fair Value | 3,999 | 19,360 | ||
Corporate Bonds (Investments) [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Cash and cash equivalents, Amortized Cost | 11,441 | |||
Cash and cash equivalents, Fair Value | 11,441 | |||
Cash [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Cash and cash equivalents, Amortized Cost | 1,141 | 3,124 | ||
Cash and cash equivalents, Fair Value | 1,141 | 3,124 | ||
Commercial Paper (Investments) [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Short-term investments, Amortized Cost | 53,605 | 36,667 | ||
Short-term investments, Gross Unrealized Gains | 106 | 14 | ||
Short-term investments, Fair Value | 53,711 | 36,681 | ||
Corporate Bonds (Investments) [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Short-term investments, Amortized Cost | 49,245 | 21,690 | ||
Short-term investments, Gross Unrealized Gains | 10 | 6 | ||
Short-term investments, Gross Unrealized Losses | (133) | (3) | ||
Short-term investments, Fair Value | 49,122 | 21,693 | ||
Asset-Backed Securities [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Short-term investments, Amortized Cost | 10,510 | 8,005 | ||
Short-term investments, Gross Unrealized Losses | (52) | |||
Short-term investments, Fair Value | 10,458 | $ 8,005 | ||
U.S. Treasury Notes [Member] | ||||
Cash Cash Equivalents And Short Term Investments [Line Items] | ||||
Short-term investments, Amortized Cost | 3,996 | |||
Short-term investments, Gross Unrealized Gains | 25 | |||
Short-term investments, Fair Value | $ 4,021 |
Cash, Cash Equivalents and Sh_4
Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Cash Cash Equivalents And Short Term Investments [Line Items] | |||
Investment in continuous unrealized loss position for more than one year | $ 0 | $ 0 | |
Available-for-sale securities that were other-than-temporarily impaired | $ 0 | $ 0 | |
Maximum [Member] | |||
Cash Cash Equivalents And Short Term Investments [Line Items] | |||
Available for sale securities contractual maturity period | 1 year |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Fair Value Measurements of Company's Financial Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Assets: | ||
Assets at fair value | $ 222,066 | $ 244,388 |
Liabilities: | ||
Derivative liability | 1,051 | 969 |
Level 1 [Member] | ||
Assets: | ||
Assets at fair value | 104,776 | 147,208 |
Level 2 [Member] | ||
Assets: | ||
Assets at fair value | 117,290 | 97,180 |
Level 3 [Member] | ||
Liabilities: | ||
Derivative liability | 1,051 | 969 |
Derivative Liability Exit Fee [Member] | ||
Liabilities: | ||
Derivative liability | 1,051 | 969 |
Derivative Liability Exit Fee [Member] | Level 3 [Member] | ||
Liabilities: | ||
Derivative liability | 1,051 | 969 |
Money Market Funds [Member] | ||
Assets: | ||
Assets at fair value | 100,755 | 147,208 |
Money Market Funds [Member] | Level 1 [Member] | ||
Assets: | ||
Assets at fair value | 100,755 | 147,208 |
Commercial Paper [Member] | ||
Assets: | ||
Assets at fair value | 57,710 | 56,041 |
Commercial Paper [Member] | Level 2 [Member] | ||
Assets: | ||
Assets at fair value | 57,710 | 56,041 |
Corporate Bonds [Member] | ||
Assets: | ||
Assets at fair value | 49,122 | 33,134 |
Corporate Bonds [Member] | Level 2 [Member] | ||
Assets: | ||
Assets at fair value | 49,122 | 33,134 |
Asset-Backed Securities [Member] | ||
Assets: | ||
Assets at fair value | 10,458 | 8,005 |
Asset-Backed Securities [Member] | Level 2 [Member] | ||
Assets: | ||
Assets at fair value | 10,458 | $ 8,005 |
U.S. Treasury Notes [Member] | ||
Assets: | ||
Assets at fair value | 4,021 | |
U.S. Treasury Notes [Member] | Level 1 [Member] | ||
Assets: | ||
Assets at fair value | $ 4,021 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) $ in Thousands | Mar. 31, 2020USD ($) |
Fair Value Measurements | |
Transfer of assets from Level 1 to Level 2 | $ 0 |
Transfer of assets from Level 2 to Level 1 | $ 0 |
Derivative Liability - Addition
Derivative Liability - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | |
May 31, 2018 | Mar. 31, 2020 | |
Derivative [Line Items] | ||
Exit Fee | $ 1.5 | |
Solar Capital and Western Alliance Bank Loan Agreement [Member] | Level 3 [Member] | ||
Derivative [Line Items] | ||
Percentage of increase in risk component | 10.00% | |
Percentage decrease in risk component | 10.00% | |
Fair value fluctuation due to increase in risk component | $ 0.1 | |
Fair value fluctuation due to decrease in risk component | $ 0.1 |
Derivative Liability - Schedule
Derivative Liability - Schedule of Changes in Fair Value (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Derivative Liability | ||
Fair value of Exit Fee derivative liability at beginning | $ 969 | $ 533 |
Change in estimated fair value of derivative liability | 82 | 37 |
Fair value of Exit Fee derivative liability at ending | $ 1,051 | $ 570 |
Borrowing (Details)
Borrowing (Details) - USD ($) $ in Thousands | May 16, 2018 | Mar. 31, 2020 | Dec. 31, 2019 |
Term Loans | |||
Amount of term loan facility | $ 50,000 | $ 51,975 | |
Base interest rate | 7.45% | ||
Equal monthly installment | $ 2,100 | ||
Percentage of premium payable on redemption of the term loan | 1.00% | ||
Amount of fee payable upon closing of the term loan | $ 500 | ||
Additional default interest rate | 4.00% | ||
Future debt payment obligations | |||
Remainder of 2020 | 2,083 | ||
2021 | 25,000 | ||
2022 | 24,892 | ||
Total principal and final fee payments | $ 50,000 | 51,975 | |
Less: Unamortized discount and debt issuance costs | (652) | ||
Less: Unaccreted value of final fee | (1,093) | ||
Loan payable | 50,230 | ||
Loan payable, current portion | 7,437 | $ 1,183 | |
Loan payable, net of current portion | $ 42,793 | $ 48,831 | |
At Maturity | |||
Term Loans | |||
Prepayment fee (as a percent) | 3.95% | ||
Prior to first anniversary of closing date | |||
Term Loans | |||
Prepayment fee (as a percent) | 3.00% | ||
After first anniversary of closing date | |||
Term Loans | |||
Prepayment fee (as a percent) | 2.00% | ||
After second anniversary to maturity date | |||
Term Loans | |||
Prepayment fee (as a percent) | 1.00% | ||
LIBOR | |||
Term Loans | |||
Floating interest rate | one-month LIBOR |
Leases - Balance Sheet and Stat
Leases - Balance Sheet and Statement of Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Additional details of the leases | |||
Right-of-use assets | $ 3,468 | $ 3,970 | |
Current portion of lease liabilities | 2,715 | 2,608 | |
Operating lease liability, net of current portion | 1,355 | $ 2,076 | |
Total operating lease liabilities | $ 4,070 | ||
Weighted-average remaining life | 1 year 6 months | ||
Weighted-average discount rate | 12.99% | ||
Facilities | |||
Operating lease expense | $ 648 | $ 648 | |
Cash paid for operating lease | $ 760 | $ 614 |
Leases - Undiscounted Cash Paym
Leases - Undiscounted Cash Payment Obligations (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Undiscounted cash payment obligations for its operating lease liabilities | ||
Remainder of 2020 | $ 2,306 | |
2021 | 2,183 | |
Total undiscounted operating lease payments | 4,489 | |
Imputed interest expenses | (419) | |
Total operating lease liabilities | 4,070 | |
Less: Current portion of operating lease liability | 2,715 | $ 2,608 |
Operating lease liability, net of current portion | $ 1,355 | $ 2,076 |
Equity Incentive Plans - Additi
Equity Incentive Plans - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | ||
Feb. 29, 2020 | Jul. 31, 2018 | Mar. 31, 2020 | Mar. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Weighted-average grant-date estimated fair value of options granted | $ 5.27 | |||
Net proceeds from stock option exercised | $ 216,000 | $ 2,000 | ||
Stock-based compensation expenses | $ 2,948,000 | $ 1,922,000 | ||
Number of shares issued upon vesting of restricted stock units | 0 | 0 | ||
Proceeds | $ 375,000 | $ 198,000 | ||
Employee Stock Purchase Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares issued under ESPP | 75,804 | |||
Purchase price | $ 4.95 | |||
Proceeds | $ 400,000 | |||
Options to Purchase Common Stock [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares, granted | 1,919,789 | |||
Number of options exercised | 141,551 | 770 | ||
Net proceeds from stock option exercised | $ 200,000 | $ 200,000 | ||
Restricted Stock Units (RSUs) [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares, granted | 0 | 0 | ||
Performance-Based Restricted Stock Units (PRSUs) [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares, granted | 903,374 | 0 | 0 | |
Number of shares, outstanding | 849,328 | |||
Number of vested shares | 0 | |||
Stock-based compensation expenses | $ 900,000 | $ 0 |
Equity Incentive Plans - Summar
Equity Incentive Plans - Summary of Weighted-Average Assumptions to Estimate Fair value of Employee Stock Options (Details) | 3 Months Ended |
Mar. 31, 2020 | |
Equity Incentive Plans | |
Expected term (years) | 6 years |
Volatility | 83.62% |
Risk-free interest rate | 1.68% |
Equity Incentive Plans - Summ_2
Equity Incentive Plans - Summary of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expenses | $ 2,948 | $ 1,922 |
Research and development | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expenses | 1,058 | 760 |
General and administrative | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expenses | $ 1,890 | $ 1,162 |
Equity Incentive Plans - Unreco
Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2020USD ($) | |
Options to Purchase Common Stock [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized Compensation Expense | $ 13,401 |
Average Vesting Period | 3 years |
Performance-Based Restricted Stock Units (PRSUs) [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized Compensation Expense | $ 602 |
Average Vesting Period | 4 months 24 days |
Employee Stock Purchase Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized Compensation Expense | $ 194 |
Average Vesting Period | 4 months 24 days |
Net Loss Per Share - Computatio
Net Loss Per Share - Computation of Basic and Diluted Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Numerator: | ||
Net loss | $ (22,373) | $ (26,144) |
Denominator: | ||
Weighted average common shares outstanding - basic and diluted | 88,880,658 | 62,546,295 |
Net loss per share - basic and diluted | $ (0.25) | $ (0.42) |
Net Loss Per Share - Additional
Net Loss Per Share - Additional Information (Details) - shares shares in Millions | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Net Loss Per Share | ||
Potential common shares that would have been included in diluted income per share were not anti-dilutive effect caused by the net loss, computed by converting these securities using the treasury stock method | 11.9 | 9.9 |
Collaboration and Licensing A_3
Collaboration and Licensing Agreements - Additional Information (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 29 Months Ended | |||||
Nov. 30, 2019USD ($)item | Mar. 31, 2018USD ($) | Dec. 31, 2017USD ($) | Nov. 30, 2017USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2017USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Revenue | $ 1,213,000 | ||||||||
Unbilled revenue | 750,000 | $ 750,000 | $ 750,000 | ||||||
Other | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Revenue | 38,000 | ||||||||
2019 KKC Agreement | Kyowa Kirin Co. Ltd | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Number of pre-clinical study-ready compounds | item | 2 | ||||||||
Number of compounds inhibiting the first undisclosed target | item | 1 | ||||||||
Upfront payment recognized | $ 10,000,000 | ||||||||
License fee receivable, first installment | $ 5,000,000 | ||||||||
Term of payment of license fee, first installment | 30 days | ||||||||
License fee receivable, Second instalment | $ 5,000,000 | ||||||||
Term of agreement | 2 years | ||||||||
Initial transaction price | $ 10,000,000 | ||||||||
Revenue | 1,200,000 | ||||||||
Change in estimates | 0 | ||||||||
Transaction price allocated to partially unsatisfied performance obligations | 8,400,000 | 8,400,000 | |||||||
Uncharged license fees | 3,400,000 | 3,400,000 | |||||||
2019 KKC Agreement | Kyowa Kirin Co. Ltd | Minimum [Member] | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Number of development candidates | item | 1 | ||||||||
Number of separate collaborative agreements | item | 1 | ||||||||
2017 KKC Agreement | Kyowa Kirin Co. Ltd | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Upfront payment recognized | $ 30,000,000 | ||||||||
Uncharged license fees | 1,000,000 | ||||||||
Upfront payment received | 30,000,000 | ||||||||
Unbilled revenue | $ 5,000,000 | ||||||||
Development milestones Received | $ 5,000,000 | ||||||||
Commercialization milestones | 78,300,000 | ||||||||
2017 KKC Agreement | Kyowa Kirin Co. Ltd | Maximum [Member] | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Development milestones | $ 55,000,000 | ||||||||
2017 KKC Agreement | Kyowa Kirin Co. Ltd | Other | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Revenue | 38,000 | $ 0 | |||||||
XuanZhu Agreement | XuanZhu | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Revenue | 0 | ||||||||
Upfront payment received | $ 750,000 | ||||||||
License fee recognized | 1,500,000 | ||||||||
Second milestone payment | $ 750,000 | ||||||||
Fosun Agreement | Fosun Pharma | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Upfront payment recognized | $ 12,000,000 | $ 12,000,000 | |||||||
Revenue | 0 | 0 | |||||||
Future development milestones | $ 110,000,000 | ||||||||
Fosun Agreement | Fosun Pharma | Maximum [Member] | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Threshold percentage of net sales for tiered royalties | 20.00% | ||||||||
Knight Agreement | Knight | |||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
Revenue | $ 0 | $ 0 | |||||||
Total payments, including an up-front payment and development and sales milestones to be received | $ 17,600,000 |
Collaboration and Licensing A_4
Collaboration and Licensing Agreements - Schedule of Changes in Deferred Revenue (Details) - 2019 KKC Agreement $ in Thousands | 3 Months Ended |
Mar. 31, 2020USD ($) | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
Balance at December 31, 2019 | $ 4,541 |
Decreases due to revenue recognized in the period for which cash has been received | (588) |
Decreases due to revenue recognized in the period for which cash has not been received | (587) |
Balance at March 31, 2020 | $ 3,366 |
Contingencies - Additional Info
Contingencies - Additional Information (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Contingencies. | ||
Contingent liabilities | $ 0 | $ 0 |